ZIOPHARM Oncology Inc (ZIOP) financial statements (2022 and earlier)

Company profile

Business Address ONE FIRST AVENUE
BOSTON, MA 02129
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments115135154171808844
Cash and cash equivalents115135154171808844
Receivables5541331
Other undisclosed current assets11141620222421
Total current assets:13115517319210511666
Noncurrent Assets
Operating lease, right-of-use asset5222211
Property, plant and equipment10864111
Deposits noncurrent assets0000000
Other noncurrent assets1111005
Total noncurrent assets:161197427
TOTAL ASSETS:14616618219810911873
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18181616121010
Accounts payable1310111
Accrued liabilities1716151511109
Debt1111111
Total current liabilities:18191717131110
Noncurrent Liabilities
Long-term debt and lease obligation4211211
Finance lease, liability4211211
Total noncurrent liabilities:4211211
Total liabilities:22211818141211
Stockholders' equity
Stockholders' equity attributable to parent1241451631809510662
Common stock0000000
Additional paid in capital888886884883779774656
Accumulated deficit(764)(741)(721)(702)(684)(668)(594)
Total stockholders' equity:1241451631809510662
TOTAL LIABILITIES AND EQUITY:14616618219810911873

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(23)(20)(19)(19)(16)(13)(15)
Operating loss:(23)(20)(19)(19)(16)(13)(15)
Nonoperating income
(Other Nonoperating income)
0000000
Net loss:(23)(20)(19)(18)(16)(13)(15)
Other undisclosed net loss attributable to parent     (61) 
Net loss available to common stockholders, diluted:(23)(20)(19)(18)(16)(74)(15)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(23)(20)(19)(18)(16)(13)(15)
Comprehensive loss, net of tax, attributable to parent:(23)(20)(19)(18)(16)(13)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: